MedTrace Logo

Sunitinib Drug Levels and Outcomes in Kidney Cancer

NCT01711268 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 35

Last updated 2014-05-15

No results posted yet for this study

Summary

Sunitinib is an oral drug used for treatment of advanced kidney cancer. The standard dose is 50mg, but many patients require a dose decrease due to side-effects. Drug levels of sunitinib vary approximately 10-fold between patients.

This study will measure blood levels of sunitinib and its metabolite, and correlate these with side-effects and the response to the treatment. The study aims to establish whether blood levels change with time, and see how useful blood levels are for monitoring patients treated with sunitinib.

Conditions

Sponsors & Collaborators

  • Western Sydney Local Health District

    lead OTHER

Principal Investigators

  • Howard Gurney, MBBS, FRACP · Crown Princess Mary Cancer Centre, Westmead

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-05-31
Primary Completion
2014-12-31
Completion
2014-12-31

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01711268 on ClinicalTrials.gov